-- Robust efficacy and evidence of a dose response from single intravitreal injection (IVT) of ADVM-022 -- -- Long-term durability beyond 1 year from single IVT injection of ADVM-022 with zero rescue injections in Cohort 1 -- -- Encouraging early data from Cohort 3 --...
REDWOOD CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced several virtual presentations of data from the...
-- Company to host conference call and webcast with key opinion leaders onMonday, May 4, 2020 at 2:15 pm PT -- REDWOOD CITY, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet...
Patients in Cohort 4 of OPTIC will Receive a Single ADVM-022 Dose of 6 x 10 ^11 vg/eye REDWOOD CITY, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in...
REDWOOD CITY, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Scott Whitcup, M.D. to the...
-- Cohort 3 dosing complete and cohort 4 screening underway in OPTIC Phase 1 trial of ADVM-022 in wet AMD -- -- New OPTIC data to be presented in May 2020 ---- Data from all four cohorts of OPTIC planned in 2020 -- -- Company to host conference call today at 1:30...
-- Arshad Khanani, M.D. to present new data from the ongoing OPTIC Phase 1 trial of ADVM-022 gene therapy in wet AMD -- REDWOOD CITY, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company...
REDWOOD CITY, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and audio...
REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Angela Thedinga has been promoted to chief...